Vepdegestrant
- Generic Name
- Vepdegestrant
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Arvinas Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT05549505
- Locations
- 🇪🇸
Clinical Trial Site, Zaragoza, Spain
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT05548127
- Locations
- 🇺🇸
Stanford Women's Cancer Center, Palo Alto, California, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸Moffitt Cancer Center - International Plaza, Tampa, Florida, United States
A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05538312
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT05463952
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: ARV-471 in combination with palbociclib (IBRANCE®)
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Arvinas Estrogen Receptor, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT04072952
- Locations
- 🇺🇸
Clinical Trial Site, Seattle, Washington, United States
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Conditions
- HER2-negative Breast CancerHormone Receptor Positive TumorAngiosarcomaTNBC - Triple-Negative Breast CancerBreast NeoplasmsBreast TumorsHER2-positive Breast CancerHormone Receptor Negative TumorBreast CancerEarly-stage Breast Cancer
- Interventions
- Drug: Standard TherapyDrug: AMG 386 with or without TrastuzumabDrug: AMG 479 (Ganitumab) plus MetforminDrug: SYD985 ([vic-]trastuzumab duocarmazine)Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug: Datopotamab deruxtecan + DurvalumabDrug: Rilvegostomig + TDXdDrug: AMG 386 and Trastuzumab
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 5000
- Registration Number
- NCT01042379
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Kansas, Westwood, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.